Long term beneficial effect of neurotrophic factors-secreting mesenchymal stem cells transplantation in the BTBR mouse model of autism

HighlightsMSC and NurOwn® treatments induced a long‐lasting effect of amelioration of autistic‐like behaviors.NurOwn® treatment had advantages over MSC treatment in terms of communication and stereotypic behavior.Both MSC and NurOwn® treatments induced a long‐lasting improvement in social behavior. Abstract Autism spectrum disorders (ASD) are neurodevelopmental disabilities characterized by severe impairment in social communication skills and restricted, repetitive behaviors. We have previously shown that a single transplantation of mesenchymal stem cells (MSC) into the cerebral lateral ventricles of BTBR autistic‐like mice resulted in an improvement across all diagnostic criteria of ASD. We suggested that brain‐derived neurotrophic factor (BDNF), a protein which supports the survival and regeneration of neurons secreted by MSC, largely contributed to the beneficial behavioral effect. In this study, we investigated the behavioral effects of transplanted MSC induced to secrete higher amounts of neurotrophic factors (NurOwn®), on various ASD‐related behavioral domains using the BTBR mouse model of ASD. We demonstrate that NurOwn® transplantation had significant advantages over MSC transplantation in terms of improving communication skills, one and six months following treatment, as compared to sham‐treated BTBR mice. Furthermore, NurOwn® transplantation resulted in reduced stereotypic behavior for as long as six months post treatment, compared to the one month improvement observed in the MSC treated mice. Notably, NurOwn® treatment resulted in improved cognitive flexibility, an improvement that was not observed by MSC treatment. Both MSC and NurOwn® transplantation induced an improvement in social behavior that lasted for six months. In conclusion, the present study demonstrates that a single transplantation of MSC or NurOwn® have long‐lasting benefits, while NurOwn® may be superior to MSC treatment.

[1]  L. R. Sutton,et al.  Identifying Individuals With Autism in a State Facility for Adolescents Adjudicated as Sexual Offenders , 2013 .

[2]  W. Wood,et al.  Hippocampal Transcriptomic and Proteomic Alterations in the BTBR Mouse Model of Autism Spectrum Disorder , 2015, Front. Physiol..

[3]  M. Kas,et al.  Dietary interventions that reduce mTOR activity rescue autistic-like behavioral deficits in mice , 2017, Brain, Behavior, and Immunity.

[4]  D. Siniscalco,et al.  Mesenchymal stem cells in treating autism: Novel insights. , 2014, World journal of stem cells.

[5]  T. Nickl-Jockschat,et al.  The role of neurotrophic factors in autism , 2011, Molecular Psychiatry.

[6]  V. Bolivar,et al.  The BTBR T + tf/J mouse model for autism spectrum disorders–in search of biomarkers , 2013, Behavioural Brain Research.

[7]  M. Gill,et al.  Increased BDNF levels and NTRK2 gene association suggest a disruption of BDNF/TrkB signaling in autism , 2010, Genes, brain, and behavior.

[8]  A. Sharma,et al.  Autologous Bone Marrow Mononuclear Cell Therapy for Autism: An Open Label Proof of Concept Study , 2013, Stem cells international.

[9]  William A. Catterall,et al.  Enhancement of Inhibitory Neurotransmission by GABAA Receptors Having α2,3-Subunits Ameliorates Behavioral Deficits in a Mouse Model of Autism , 2014, Neuron.

[10]  D. Offen,et al.  Safety of repeated transplantations of neurotrophic factors-secreting human mesenchymal stromal stem cells , 2014, Clinical and Translational Medicine.

[11]  E. Melamed,et al.  Intrastriatal transplantation of neurotrophic factor-secreting human mesenchymal stem cells improves motor function and extends survival in R6/2 transgenic mouse model for Huntington's disease , 2012, PLoS currents.

[12]  E. Melamed,et al.  Safety and Clinical Effects of Mesenchymal Stem Cells Secreting Neurotrophic Factor Transplantation in Patients With Amyotrophic Lateral Sclerosis: Results of Phase 1/2 and 2a Clinical Trials. , 2016, JAMA neurology.

[13]  Maureen S. Durkin,et al.  Prevalence and Characteristics of Autism Spectrum Disorder Among Children Aged 8 Years — Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2012 , 2018, Morbidity and mortality weekly report. Surveillance summaries.

[14]  Byung-Jo Kim,et al.  Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism , 2013, Journal of Translational Medicine.

[15]  J. Crawley,et al.  GABAB Receptor Agonist R-Baclofen Reverses Social Deficits and Reduces Repetitive Behavior in Two Mouse Models of Autism , 2015, Neuropsychopharmacology.

[16]  J. Crawley,et al.  Behavioral and Neuroanatomical Phenotypes in Mouse Models of Autism , 2015, Neurotherapeutics.

[17]  Altered Cytokine and BDNF Levels in Autism Spectrum Disorder , 2013, Neurotoxicity Research.

[18]  Y. Cohen,et al.  Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease. , 2009, Stem cells and development.

[19]  Tony Charman,et al.  Diagnosis of autism spectrum disorder: reconciling the syndrome, its diverse origins, and variation in expression , 2016, The Lancet Neurology.

[20]  A. Thurm,et al.  Pharmacotherapy for the Core Symptoms in Autistic Disorder: Current Status of the Research , 2013, Drugs.

[21]  E. Melamed,et al.  Induction of Adult Human Bone Marrow Mesenchymal Stromal Cells into Functional Astrocyte-Like Cells: Potential for Restorative Treatment in Parkinson’s Disease , 2009, Journal of Molecular Neuroscience.

[22]  D. Offen,et al.  Mesenchymal Stem Cell Transplantation Promotes Neurogenesis and Ameliorates Autism Related Behaviors in BTBR Mice , 2016, Autism research : official journal of the International Society for Autism Research.

[23]  J. N. Crawley,et al.  Unusual repertoire of vocalizations in adult BTBR T+tf/J mice during three types of social encounters , 2011, Genes, brain, and behavior.

[24]  A. Keating,et al.  Therapeutic properties of mesenchymal stem cells for autism spectrum disorders. , 2015, Medical hypotheses.

[25]  Daniel Morton,et al.  Histopathologic characterization of the BTBR mouse model of autistic-like behavior reveals selective changes in neurodevelopmental proteins and adult hippocampal neurogenesis , 2011, Molecular autism.

[26]  E. Hollander,et al.  Mesenchymal stem cells in autism spectrum and neurodevelopmental disorders: pitfalls and potential promises , 2015, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[27]  T. Kimchi,et al.  Acetylcholine Elevation Relieves Cognitive Rigidity and Social Deficiency in a Mouse Model of Autism , 2014, Neuropsychopharmacology.

[28]  L. Ricceri,et al.  Reduced social interaction, behavioural flexibility and BDNF signalling in the BTBR T+tf/J strain, a mouse model of autism , 2013, Behavioural Brain Research.